TG Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Good afternoon, everyone. Thanks for joining us here at the Goldman Sachs Global Healthcare Conference, including everyone joining us virtually. Thrilled to have on stage with us today the Chief Executive Officer of TG Therapeutics, Mike Weiss.
Questions & Answers
And maybe we'll just turn it to you to start with kind of an overview of the business, key priorities over the intermediate term. And I've been asking everyone how do you think about the core competencies of your business?
Sure. And thanks for having us. Always delighted to be in lovely, Miami. So at TG, we try to keep things relatively simple. We've got our BRIUMVI now approved for relapsing forms of MS.
We're about 3.5 years-ish into the launch. Our target this year, I think we're at $885 million to $900 million in terms of revenue guidance for the US alone. And in terms of key priorities for the year, one is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
